RBR-6kkmskk
Not yet recruiting
未知
Safety and efficacy in the treatment of primary open-angle glaucoma with Triplenex compared to isolated medications
centro oftalmologico de minas gerais0 sitesJune 7, 2021
Conditionsopen angle glaucoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- open angle glaucoma
- Sponsor
- centro oftalmologico de minas gerais
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 years of age minimum; ocular hypertension with intraocular pressure levels greater than or equal to 21 mmHg; carrier of open angle glaucoma presenting intraocular pressure levels greater than or equal to 18 mmHg; reduction of intraocular pressure in relation to baseline values ??\<30%; patients intolerant of current treatment due to ocular surface symptoms; meet the criteria of the control group for at least 3 months;
Exclusion Criteria
- •monoaminoxidase users; patients with asthma or severe chronic obstructive pulmonary disease; patients with sinus bradycardia, atrioventricular block of 2 or 3 degrees not controlled with a pacemaker, decompensated congestive heart failure; patient known to be allergic to any of the components of TRIPLENEX; pregnant patients; patients with any corneal irregularity that hinder the perfect reading of intraocular pressure by Goldman's tonometer (intra stromal ring, corneal transplant or scars with important corneal thinning); patients undergoing anti\-glaucoma surgical procedures in the last 3 months (laser trabeculoplasty; incisional procedures such as trabeculectomy; glaucoma drainage devices, among others)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Safety of different doses of the antimalarial drug Primaquine on Vivax Malaria Treatment in patients Deficient of the enzyme Glucose-6-phospate DehydrogenaseAnemia due to glucose-6-phospate dehydrogenase deficiencymalaria by Plasmodium vivaxB51.8D55.0RBR-2rcm2gFundação de Medicina Tropical Heitor Vieira Dourado - FMTHVD
Recruiting
Not Applicable
Efficacy and safety of initial treatment (combination immunotherapy or chemotherapy + ICI) in advanced non-small cell lung cancer patients (TPS 1-49%): A multicenter retrospective observational study (TOPGAN2023-01)non small cell carcinomaJPRN-UMIN000052228department of respiratory medicine hirosaki university graduate school of medicine300
Completed
Phase 4
Efficacy and safety of regular treatment with procaterol and budesonide inhalation suspension for young children with moderate persistent asthma.Bronchial AsthmaJPRN-UMIN000003492niversity of Toyama, Faculty of Medicine, Department of Pediatrics50
Completed
Phase 2
Efficacy and feasibility of first-line treatment with risk-adapted dose-adjusted EPOCH-R (DA-EPOCH-R) in patients with Burkitt lymphoma. A phase II clinical trial.Burkitt lymphomahighly aggressive B cell lymphoma10025320NL-OMON36941Vrije Universiteit Medisch Centrum22
Active, not recruiting
Not Applicable
A trial to investigate treatment with EPOCH-R in patients with Burkitt lymphoma, by adapting the dose to the risk classification of the disease.Burkitt lymphomaMedDRA version: 14.1Level: HLTClassification code 10006596Term: Burkitt's lymphomasSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2012-003141-16-NLVU University Medical Center